A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol fumarate (BGF) metered dose inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants with Chronic Obstructive Pulmonary Disease (COPD). - ATHLOS

Study identifier:D5988C00001

ClinicalTrials.gov identifier:NCT06067828

EudraCT identifier:N/A

CTIS identifier:2022-502274-16-00

Recruiting

Official Title

A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants with COPD (ATHLOS)

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 3

Healthy volunteers

Study drug

Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo

Sex

All

Estimated Enrollment

180

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 24 Oct 2023

Estimated Primary Completion Date: 24 Aug 2025

Estimated Study Completion Date: 25 Aug 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2024 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

• Participant must be male or female, 40 to 80 years of age inclusive, at the time of signing the informed consent.
• Participant must have:
- a diagnosis of COPD confirmed by a post-bronchodilator Forced expiratory volume (FEV1)/ Forced vital capacity (FVC) < 0.7 at Visit 1
- a post-bronchodilator FEV1 ≥ 30% and <80% predicted normal (moderate to severe COPD) at Visit 1.
- a score of ≥ 2 on the modified Medical Research Council at Visit 1.
- pre-bronchodilator FRC of > 120% of predicted normal FRC values at Visit 1.
- a constant work rate test endurance time of 3 to 8 minutes at Visit 2.
• Participant must be on a stable dose of mono-or dual inhaled maintenance COPD treatment for at least 6 weeks.
• Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking
• Body mass index < 40 kg/m2.
• Male and Female participants (not applicable for female participants with non-childbearing potential) and their partners must use an acceptable method of contraception.

Exclusion Criteria

• A current diagnosis of asthma, asthma- COPD-overlap, or any other chronic respiratory disease other than COPD such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease and pulmonary hypertension.
• Historical or current evidence of a clinically significant disease
• Participants on oxygen therapy or that desaturate significantly (<82%) during exercise.
• Participants who are enrolled or entering a pulmonary rehabilitation program during the study.
• Participants who have cancer that has not been in complete remission for at least 5 years.
• Participants with a diagnosis of narrow-angle glaucoma that has not been adequately treated and/or change in vision that may be relevant, in the opinion of the investigator.
• Participants with symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that, in the opinion of the investigator, is clinically significant.
• Participants who have a history of hypersensitivity to β2-agonists, budesonide or any other corticosteroid components, glycopyrronium or other muscarinic anticholinergics, or any component of the MDI or dry powder inhaler.
• Participant with resting (5 minutes) oxygen saturation SaO2 in room air ≤ 85%.
• A COPD exacerbation that requires hospitalization within 12 months prior to Visit 1 or a COPD exacerbation that requires systemic corticosteroids or antibiotics within 4 months of Visit 1.
• Participants with contraindications to cardiopulmonary exercise testing (CPET).
• Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening period.
• Participants with lung lobectomy, lung volume reduction or lung transplantation.
• Unable to withhold short-acting bronchodilators for 6 hours prior to lung function testing at each study visit.
• Known history of drug or alcohol abuse within 12 months.
• Any regular recreational use of marijuana in the 12 months.

Sort by status

No locations available

Arms	Assigned Interventions
Active Comparator: BGF MDI Pressurized MDI fixed combination product of Budesonide 160 μg, Glycopyrronium 7.2 μg, and Formoterol Fumarate 4.8 μg per actuation.	Drug: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
Active Comparator: BFF MDI Pressurized MDI fixed combination product of Budesonide 160 μg and Formoterol Fumarate 4.8 μg per actuation.	Drug: Treatment B: Budesonide and Formoterol Fumarate Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
Placebo Comparator: Placebo Placebo as pressurized inhalation suspension.	Drug: Treatment C : Placebo Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]